Drug profile · INN
chlorothiazide
DIUPRES-500
chlorothiazide (DIUPRES-500) is a thiazide-sensitive sodium-chloride cotransporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — chlorothiazide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 11
- Data quality
- 0.84
Quick answer
chlorothiazide (DIUPRES-500) is a thiazide-sensitive sodium-chloride cotransporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Thiazide-sensitive sodium-chloride cotransporter inhibitor
Primary target: Solute carrier family 12 member 3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
- PI23/00797
- olmesartan alone or in combination with hydrochlorothiazide
- Losartan potassium/Hydrochlorothiazide
- Moexipril HCl/hydrochlorothiazide 15/25 mg tablets
- Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg
- Randomized for not applicable (submitted trial is bioavailability)
- Candesartan and Hydrochlorothiazide
- Candesartan cilexetil and hydrochlorothiazide
Related & competitor drugs
Frequently asked questions
What is chlorothiazide?
chlorothiazide (DIUPRES-500) is a thiazide-sensitive sodium-chloride cotransporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for chlorothiazide?
DIUPRES-500 is a marketed brand name for chlorothiazide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of chlorothiazide?
chlorothiazide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.